Abstract
Neurodegenerative disorders are increasingly identified as one of the major causes of epilepsy. The relationship of epileptic activity to Alzheimer’s disease (AD) is of clinical importance. Voltage-gated sodium channel (VSC) is one of the best targets in the treatment of epilepsy while β-secretase (BACE) has long been observed as a curative target for AD. To explore a possible link between the treatment of AD and epilepsy, the molecular interactions of recently Food and Drug Administration approved antiepileptic drug Aptiom (Eslicarbazepine acetate) with BACE and VSC were studied. Docking study was performed using ‘Autodock4.2’. Hydrophobic and pi-pi interactions play critical role in the correct positioning of Eslicarbazepine acetate within the catalytic site of VSC and BACE enzyme to permit docking. Free energy of binding (ΔG) of ‘Eslicarbazepine acetate-VSC’ interaction and ‘Eslicarbazepine acetate-CAS domain of BACE’ interaction was found to be -5.97 and -7.19 kcal/mol, respectively. Hence, Eslicarbazepine acetate might act as a potent dual inhibitor of BACE and VSC. However, scope still remains in the determination of the three-dimensional structure of BACE- Eslicarbazepine acetate and VSC-Eslicarbazepine acetate complexes by X-ray crystallography to validate the described data. Further, Aptiom (Eslicarbazepine acetate) could be expected to form the basis of future dual therapy against epilepsy associated neurological disorders.
Keywords: Alzheimer's disease, β-secretase, epilepsy, eslicarbazepine acetate, voltage-gated sodium channel.
CNS & Neurological Disorders - Drug Targets
Title:Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study
Volume: 13 Issue: 7
Author(s): Sibhghatulla Shaikh, Syed M.D. Rizvi, Nida Hameed, Deboshree Biswas, Mahiuddin Khan, Shazi Shakil and Mohammad A. Kamal
Affiliation:
Keywords: Alzheimer's disease, β-secretase, epilepsy, eslicarbazepine acetate, voltage-gated sodium channel.
Abstract: Neurodegenerative disorders are increasingly identified as one of the major causes of epilepsy. The relationship of epileptic activity to Alzheimer’s disease (AD) is of clinical importance. Voltage-gated sodium channel (VSC) is one of the best targets in the treatment of epilepsy while β-secretase (BACE) has long been observed as a curative target for AD. To explore a possible link between the treatment of AD and epilepsy, the molecular interactions of recently Food and Drug Administration approved antiepileptic drug Aptiom (Eslicarbazepine acetate) with BACE and VSC were studied. Docking study was performed using ‘Autodock4.2’. Hydrophobic and pi-pi interactions play critical role in the correct positioning of Eslicarbazepine acetate within the catalytic site of VSC and BACE enzyme to permit docking. Free energy of binding (ΔG) of ‘Eslicarbazepine acetate-VSC’ interaction and ‘Eslicarbazepine acetate-CAS domain of BACE’ interaction was found to be -5.97 and -7.19 kcal/mol, respectively. Hence, Eslicarbazepine acetate might act as a potent dual inhibitor of BACE and VSC. However, scope still remains in the determination of the three-dimensional structure of BACE- Eslicarbazepine acetate and VSC-Eslicarbazepine acetate complexes by X-ray crystallography to validate the described data. Further, Aptiom (Eslicarbazepine acetate) could be expected to form the basis of future dual therapy against epilepsy associated neurological disorders.
Export Options
About this article
Cite this article as:
Shaikh Sibhghatulla, Rizvi M.D. Syed, Hameed Nida, Biswas Deboshree, Khan Mahiuddin, Shakil Shazi and Kamal A. Mohammad, Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study, CNS & Neurological Disorders - Drug Targets 2014; 13 (7) . https://dx.doi.org/10.2174/1871527313666140917121600
DOI https://dx.doi.org/10.2174/1871527313666140917121600 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticonvulsant and Neurotoxicity of Some Novel 1-([1,3,4]thiadiazino[6,5- b]indol-3-yl Semicarbazides
Central Nervous System Agents in Medicinal Chemistry Tailored Multi-Target Agents. Applications and Design Considerations
Current Pharmaceutical Design Pharmacotherapeutic Potential of Garlic in Age-Related Neurological Disorders
CNS & Neurological Disorders - Drug Targets Antioxidant Capacity, Phytochemical Analysis and Identification of Active Compounds in Anchomanes difformis
The Natural Products Journal New Route to Synthesize Fluorine Substituted Lamotrigine Drug Analogues as an Anti-Inflammatory Agent
Current Organic Synthesis Editorial (Thematic Issue: Targeting Transporters for CNS Drug Delivery)
Current Pharmaceutical Design Role of Mesenchymal Stem Cells in Dermal Repair in Burns and Diabetic Wounds
Current Stem Cell Research & Therapy Sympathetic Nervous System Dysfunction in Multiple Sclerosis, Linking Neurodegeneration to a Reduced Response to Therapy
Current Pharmaceutical Design Therapeutic Potential of Group III Metabotropic Glutamate Receptors
Current Medicinal Chemistry Cardioembolic Stroke: Clinical Features, Specific Cardiac Disorders and Prognosis
Current Cardiology Reviews [General Articles] Natriuretic Peptides in Alcohol Withdrawal: Central and Peripheral Mechanisms
Current Medicinal Chemistry A Review of Lysergic Acid Diethylamide (LSD) in the Treatment of Addictions: Historical Perspectives and Future Prospects
Current Drug Abuse Reviews Radiopharmaceuticals in Neurological and Psychiatric Disorders
Current Clinical Pharmacology mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Method to Assess Interactivity of Drugs with Nonparallel Concentration Effect Relationships
Current Cancer Drug Targets Inflammasome and Atherogenesis
Current Pharmaceutical Design The Plastic Phenomenon Underlying the Associative Processes in the Addictive Properties of Diazepam and Other Psychoactive Drugs
Mini-Reviews in Medicinal Chemistry ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug Interactions
Current Drug Targets Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Current Cancer Drug Targets